Your browser doesn't support javascript.
loading
Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia.
How, Joan; Leiva, Orly; Bogue, Thomas; Fell, Geoffrey G; Bustoros, Mark W; Connell, Nathan T; Connors, Jean M; Ghobrial, Irene M; Kuter, David J; Mullally, Ann; Neuberg, Donna; Zwicker, Jeffrey I; Fogerty, Annemarie E; Hobbs, Gabriela S.
Affiliation
  • How J; Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School Boston, MA, 02115, USA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, H
  • Leiva O; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • Bogue T; Division of Hematology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
  • Fell GG; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
  • Bustoros MW; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School Boston, MA, 02115, USA.
  • Connell NT; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School Boston, MA, 02115, USA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • Connors JM; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School Boston, MA, 02115, USA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • Ghobrial IM; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School Boston, MA, 02115, USA.
  • Kuter DJ; Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
  • Mullally A; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School Boston, MA, 02115, USA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • Neuberg D; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
  • Zwicker JI; Division of Hematology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
  • Fogerty AE; Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
  • Hobbs GS; Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA. Electronic address: ghobbs@partners.org.
Leuk Res ; 98: 106459, 2020 11.
Article de En | MEDLINE | ID: mdl-33022566
ABSTRACT
Pregnancy in essential thrombocythemia (ET) is associated with increased risk of obstetric complications. We retrospectively evaluated risk factors in 121 pregnancies in 52 ET women seen at 3 affiliate hospitals. Univariable and multivariable analyses were performed at the α = 0.10 level. Cell counts were characterized throughout pregnancy and correlated with outcomes using logistic modeling. The overall live birth rate was 69 %. 48.7 % of all women experienced a pregnancy complication, the most common being spontaneous abortion, which occurred in 26 % of all pregnancies. Maternal thrombosis and hemorrhage rates were 2.5 % and 5.8 %. On multivariable analysis, aspirin use (OR 0.29, p = 0.014, 90 % CI 0.118-0.658) and history of prior pregnancy loss (OR 3.86, p = 0.011, CI 1.49-9.15) were associated with decreased and increased pregnancy complications, respectively. A Markov model was used to analyze the probability of a future pregnancy complication based on initial pregnancy outcome. An ET woman who suffers a pregnancy complication has a 0.594 probability of a subsequent pregnancy complication, compared to a 0.367 probability if she didn't suffer a complication. However, despite this elevated risk, overall prognosis is good, with a >50 % probability of a successful pregnancy by the third attempt. Platelet counts decreased by 43 % in ET during pregnancy, with nadir at delivery and prompt recovery in the postpartum period. Women with larger declines in gestational platelet counts were less likely to suffer complications (p = 0.083). Our study provides important guidance to physicians treating ET women during pregnancy, including counseling information regarding risk assessment and expected trajectory of platelet levels.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Complications hématologiques de la grossesse / Avortement spontané / Naissance vivante / Thrombocytémie essentielle / Modèles biologiques Type d'étude: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limites: Adult / Female / Humans / Pregnancy Langue: En Journal: Leuk Res Année: 2020 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Complications hématologiques de la grossesse / Avortement spontané / Naissance vivante / Thrombocytémie essentielle / Modèles biologiques Type d'étude: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limites: Adult / Female / Humans / Pregnancy Langue: En Journal: Leuk Res Année: 2020 Type de document: Article
...